Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of HRS-8364 in advanced solid tumors
CTR20260708Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-8364 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Mar 2026; status: active.
02
Drugs
HRS-8364
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260708.